Showing 1 - 10 of 1,050
challenge, with manufacturing mostly concentrated in the US and Europe for high-value mRNA vaccines, and China and India for …
Persistent link: https://www.econbiz.de/10014579804
Persistent link: https://www.econbiz.de/10011393507
Compared with developed economies, health expenditure in China is not particularly high on a per capita basis or as a share of Gross Domestic Product (GDP). Similarly, pharmaceutical expenditure in comparative perspective is not particularly high on a per capita basis or as a percentage of GDP....
Persistent link: https://www.econbiz.de/10012247334
This paper examines the financing, pricing, and utilization of pharmaceuticals in China the pharmaceutical system as it …
Persistent link: https://www.econbiz.de/10012247481
India for traditional platforms and high-volume production. Countries with domestic COVID-19 vaccine manufacturing capacity …
Persistent link: https://www.econbiz.de/10014578934
Persistent link: https://www.econbiz.de/10010523369
Persistent link: https://www.econbiz.de/10010523456
"Many developing countries operate geographically delineated economic areas in the form of export processing zones, special industrial zones, or free trade zones. This paper provides an overview of the application of World Trade Organization disciplines to incentive programs typically employed...
Persistent link: https://www.econbiz.de/10011394186
"The records of traditional safeguard provisions of the General Agreement on Tariffs and Trade and the World Trade Organization provides useful information about how a special agricultural safeguard might be made effective. The success of existing safeguard or flexibility provisions to sustain...
Persistent link: https://www.econbiz.de/10011394221